Educational CME Accredited Programme

Sunday 30 May 11:00-12:15

Can we really get to LDL goal in clinical practice?

Chair:
  • Christoph Binder, Austria
  • Lale Tokgözoğlu, Turkey

Intensive Lipid lowering- moving beyond statins alone

Luis Masana, Reus, Spain

Science versus reality: Real life Clinical Cases

Alberto Zambon, Padua, Italy

Which patient needs the PCSK9 inhibitors most?

Wouter Jukema, Leiden, The Netherlands

EAS have independently organised all matters related to this 75-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Sunday 30 May 12:45-14:00

Novel pathways for intensive lipid lowering

Chair:
  • Katariina Öörni, Finland
  • Kausik Ray, United Kingdom

Intensive Lipid lowering with Double or Triple combination therapy

Stephen Nicholls, Australia

Statin associated muscle symptoms nocebo or real and how to handle

Eric Stroes, Amsterdam, The Netherlands

Why do we need additional LDL-C lowering and how can we target the LDL receptor via a different mechanisms

Ulrich Laufs, Germany

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.

 


Sunday 30 May 14:30-15:45

Overcoming barriers to population health-through siRNA based therapies

Chair:
  • Alberico Catapano, Italy
  • Lale Tokgözoğlu, Turkey

Barriers to Population based Preventive strategies

Ann Marie Navar, Texas, USA

Prevention at a population level-putting theory into practice

Kausik Ray, London, United Kingdom

siRNA- a panacea for population based prevention covering safety and mechanism and efficacy

Wolfgang Koenig, Munich, Germany

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Sunday 30 May 18:00-19:15

Addressing residual risk beyond LDL-c in high or very high-risk patients

Chair:
  • Alberico Catapano, Italy
  • Vesa Olkkonen, Finland

A tale of two trials

Ulrich Laufs, Germany

Are all omegas 3 made equal or Omega 3s – All for one and one for all?

R. Preston Mason, Boston, USA

Seeing is believing

Matthew J. Budoff, Los Angeles, USA

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Monday 31 May 14:30-15:45

Prioritising the high-risk patient- when good is not good enough

Chair:
  • Raman Puri, India
  • Kausik Ray, United Kingdom

Modern dyslipidemia management in ACS

Ulf Landmesser, Berlin, Germany

PCSK9i: What have we learnt, what else needs clarification?

Gilles Lambert, Sainte Clotilde, France

Who will benefit most from PCSK9i?

Eric Stroes, Amsterdam, The Netherlands

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Tuesday 01 June 13:30-14:45

PPAR as a therapeutic target -more than meets the eye?

Chair:

Evolving Concepts- Moving from PPAR to SPARM

Bart Steals, France

Fibrates to date - a bridge too far

Henry Ginsberg, New York, USA

Will PROMINENT be really prominent?

Aruna Pradhan, Massachusetts, USA

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


 

Congress time zone: EEST (Eastern European Summer Time, Helsinki, UTC/GMT +2)

Share this: